<p>A new report on a promising potential coronavirus treatment produced by Gilead Sciences have sent stocks surging — Dow Jones Industrial Average futures jumping 789 points, S&amp;P 500 futures rising 2.9%, and Nasdaq 100 futures climbing 2%.</p>
<p>&#8220;The premarket moves put the S&amp;P 500 on track for its first back-to-back weekly gains since early February,&#8221; <a href="https://www.cnbc.com/2020/04/16/sp-500-etf-jumps-2percent-after-hours-on-report-gilead-drug-showing-effectiveness-treating-coronavirus.html">CNBC</a> reports. &#8220;Through Thursday’s close, the S&amp;P 500 has risen 0.35%, while the Nasdaq Composite climbed 4.65%, lifted by double-digit gains in Amazon and Netflix. The 30-stock Dow was down about 0.7% this week through Thursday, dragged down by JPMorgan as interest rates tumbled.&#8221;</p>
<p>Shares for Gilead, which is coordinating the clinical trials, surged by more than 13% after a report by <a href="https://www.statnews.com/2020/04/16/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment/">STAT</a> detailed the extremely promising results out of a Chicago hospital that is part of a larger clinical study on the effectiveness of the new potential treatment.</p>
<p>Analysts are pointing to the report as the key factor positively impacting the market. &#8220;An effective treatment is a huge deal and would create a path to open the economy and resume normal ‘social activities’ way sooner than a vaccine,&#8221; said Fundstrat Global Advisors researcher Tom Lee, as reported by CNBC. &#8220;A treatment is safer and more scalable because it is only given to people who need to be treated.&#8221;</p>
<p>On Thursday, STAT detailed the early clinical trial results of Gilead Sciences’ antiviral medicine Remdesivir in a test involving 125 people at a Chicago hospital. Nearly all of the patients who were treated with the antiviral drug experienced &#8220;rapid recoveries in fever and respiratory symptoms&#8221; and were &#8220;discharged in less than a week.&#8221; STAT reports:</p>
<blockquote><p><a href="https://www.statnews.com/2020/03/16/remdesivir-surges-ahead-against-coronavirus/">Remdesivir</a> was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.</p>
<p>The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.</p></blockquote>
<p>The infectious disease specialist heading up the Chicago study, the University of Chicago&#8217;s Kathleen Mullane, said that only two of the 125 severely ill patients died, while most of them have already been discharged. Mullane underscored that the study is not extensive enough to yet draw conclusions and does not include a placebo group, but said that when they start to use the drug, fever curves tend to fall rapidly.</p>
<p>&#8220;Fever is now not a requirement for people to go on trial, we do see when patients do come in with high fevers, they do [reduce] quite quickly,&#8221; said Mullane. &#8220;We have seen people come off ventilators a day after starting therapy. So, in that realm, overall our patients have done very well&#8230; Most of our patients are severe and most of them are leaving at six days, so that tells us duration of therapy doesn’t have to be 10 days. We have very few that went out to 10 days, maybe three.&#8221;</p>
<p>Along with hydroxylchloroquine, remdesivir is one of the drugs President Trump has pointed to as a potential treatment for COVID-19. The drug, Trump said last month, &#8220;seems to have a very good result.&#8221;</p>
<p>The Chicago clinical trial is one of many that are being run concurrently by other institutions. &#8220;Gilead’s severe Covid-19 study includes 2,400 participants from 152 different clinical trial sites all over the world,&#8221; STAT explains. &#8220;Its moderate Covid-19 study includes 1,600 patients in 169 different centers, also all over the world. The trial is investigating five- and 10-day treatment courses of remdesivir.&#8221;</p>
<p>While no other data has yet been released, and the Chicago results are not nearly enough to be conclusive, &#8220;excitement is high&#8221; about the treatment&#8217;s potential, the outlet notes.</p>
<div class="MidResponsive-midResponsiveContainer">
<div class="group">
<p>As CNBC highlights, the after plummeting from records highs in February, stocks have rallied since March 23 as cases of coronavirus globally began to plateau. &#8220;Since late March, the S&amp;P 500 has jumped more than 25% while the Dow has gained 26.6% in that time,&#8221; the outlet notes.</p>
<p>While the stock market is bouncing back, some <a href="https://www.dailywire.com/news/economy-is-falling-off-a-cliff-another-5-2-million-americans-filed-jobless-claims-last-week-totaling-22-million-in-last-month">22 million</a> Americans have filed for unemployment amid widespread &#8220;stay-at-home&#8221; orders.</p>
<p><i>This report has been expanded to include more information about the Chicago study. </i></p>
</div>
</div>

<script async src="https://www.instagram.com/embed.js"></script>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<script async src="https://www.tiktok.com/embed.js"></script><div data-widget-host="revcontent" data-pub-id="165152" data-widget-id="290588"></div><script src="https://delivery.revcontent.com/165152/290588/widget.js"></script>

Report On Promising New Antiviral Treatment Sends Stocks Surging

CONTINUE READING

One Of Most Sacred Sites For Jews & Christians To Be Fully Opened To Public: ‘Miracle’ Pool Of Siloam

Tuesday | October 5th, 2021

Monday | October 4th, 2021

Friday | October 1st, 2021

Monday | September 27th, 2021

Saturday | September 25th, 2021

News and Commentary

COVID

Donald Trump

A video goes viral showing a baby being refused his mother by two gay "dads". This is just the tip of the iceberg, which is why we will have an important discussion today about surrogacy. 

Hour 1

The Matt Walsh Show

Ep. 1765 - This Video Is One Of The Worst Things I've Seen In A Long Time 

The Strait of Hormuz officially opens for business (kind of), the Pope makes “shocking” comments on immigration, and President Trump promises UFO disclosure at TPUSA. 


The Michael Knowles Show

Ep. 1956 -  Pope Leo's "SHOCKING" Immigration Comments EXPLAINED

A false miscreed has corrupted our leadership class.


The Andrew Klavan Show

Ep. 1275 - Dumb, Dumber and Progressive

President Trump announces a 10-day ceasefire between Lebanon and Israel, a murder-suicide involving former Democratic Lieutenant Governor Justin Fairfax shakes Virginia, and France and Britain hold a conference to secure the Strait of Hormuz – after the Iranian conflict ends. Get the facts first with Morning Wire.

- - -

Ep. 2738

- - -

Wake up with new Morning Wire merch: https://bit.ly/4lIubt3

- - -

Today's Sponsors:

Alliance Defending Freedom - Visit https://JoinADF.com/WIRE or text 'WIRE' to 83848 to learn more.

Pocket Hose - Text MORNING to 64000 to get a FREE pocket pivot and their 10-pattern sprayer with the purchase of ANY size Copper Head hose. Message and data rates may apply.

Morning Wire

U.S. Expands Hormuz Blockade & VA Fairfax Deaths Investigated | 4.17.26

U.S. Expands Hormuz Blockade & VA Fairfax Deaths Investigated | 4.17.26 [Member Exclusive]

A ceasefire goes into effect between Israel and Lebanon, a tragic murder-suicide rocks Virginia, and Dairy Queen deploys AI in the drive-thru. Get the facts first with Evening Wire.
- - -
Ep. 2737
- - -
Wake up with new Morning Wire merch: https://bit.ly/4lIubt3 
- - -
Today’s Sponsor:

Alliance Defending Freedom - Visit https://JoinADF.com/WIRE or text “WIRE” to 83848 to learn more.


Menu

— News and Commentary —

Report On Promising New Antiviral Treatment Sends Stocks Surging